Overview

Anecortave Acetate Risk-Reduction Trial (AART)

Status:
Terminated
Trial end date:
2008-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study was to demonstrate that Anecortave Acetate for Depot Suspension (15 mg or 30 mg) is safe and effective in arresting the progression of non-exudative (dry) age-related macular degeneration in patients who are at risk for progressing to exudative (wet) age-related macular degeneration.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Alcon Research
Treatments:
Anecortave
Hydrocortisone
Criteria
Inclusion Criteria:

- Dry AMD in study eye, Wet AMD in non-study eye;

- Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

- Under 50;

- Other protocol-defined exclusion criteria may apply.